Table 4.
Univariate | Multivariate | |||||
---|---|---|---|---|---|---|
Risk factors | β-estimate | Exp (B) CL 95% | p-value | β-estimate | Exp (B) CL 95% | p-value |
Gender | 0.8 | 0.5–1.4 | 0.5 | 1.3 | 0.5–3.8 | 0.6 |
Age of diagnose [years] | 1.0 | 0.9–1.0 | 0.07 | 0.9 | 0.9–1.0 | 0.8 |
Presence of IBD | 1.7 | 0.9–3.4 | 0.1 | 0.8 | 0.3–1.9 | 0.8 |
Presence of dominant stenosis | 2.6 | 1.4–4.9 | 0.003 | 3.3 | 1.1–9.8 | 0.04 |
Mayo Risk score | 1.7 | 1.3–2.2 | 0.001 | 1.5 | 1.0–2.1 | 0.03 |
Immunosuppression | 0.5 | 0.1–2.1 | 0.4 | 0.0 | 0.0–0.0 | 1.0 |
Biochemical response | 2.0 | 1.2–3.4 | 0.01 | 2.3 | 1.1–5.4 | 0.04 |
Elevated Serum IgG-levels | 2.4 | 1.1–5.0 | 0.02 | 2.4 | 1.0–5.7 | 0.04 |
Table shows prospective factors for longer survival until death or liver transplantation. In univariate analysis Mayo Risk Score (MRS), presence of dominant stenosis, biochemical response to UDCA and elevated serum IgG levels were associated with reduced survival. In multivariate analysis, MRS, presence of dominant stenosis, biochemical response to UDCA and elevated serum IgG-levels were independently associated with reduced transplantation-free survival (p < 0.05). Bold values indicates significant P-values (<0.05)